Jager, G., Hofler, G., Linkesch, W. and Neumeister, P. (2004) Occurrence of a myelodysplastic syndrome (MDS) during first-line 2-chloro-deoxyadenosine (2-CDA) treatment of a low-grade gastrointestinal MALT lymphoma. Case report and review of the literature. Haematologica, 89, ECR1-3.?

has been cited by the following article:

• TITLE: Occurrence of myelodysplastic syndrome during paclitaxel- and carboplatin-based chemotherapy for recurrent ovarian cancer: Case report

  AUTHORS: Hiroshi Takagi, Satoshi Ichigo, Kazutoshi Matsunami, Haruna Takagi, Tsuneko Ikeda, Takayuki Murase, Atsushi Imai

  KEYWORDS: Chemotherapy-Related Myelodysplastic Syndrome; Ovarian Cancer; Platinum; Taxane

  JOURNAL NAME: Open Journal of Obstetrics and Gynecology, Vol.3 No.2, March 13, 2013

  ABSTRACT: Platinum and taxane have significant activity as key drugs in current treatment of advanced ovarian cancer. While myelodysplastic syndrome (MDS) and acute leukemia are wellknown secondary disease after administration of chemotherapy, particularly with alkylating agents, they have only rarely been reported in the context of ovarian cancer treatment. In this case report a 59-year-old Japanese developed a MSD during ongoing second induction chemotherapy with carboplatin and paclitaxel for recurrent ovarian cancer. Her second induction began 9 months after completion of her first course of chemotherapy. Cytogenetic analyses showed typical chromosomal aberration. Although the finding of pancytopenia is also seen during chemotherapy without MSD/acute leukemia, bone marrow aspiration and biopsy should be considered to confirm the clinical suspicion of the lifethreatening disease when encountered persistent pancytopenia following carboplatin and paclitaxel-based chemotherapy in an ovarian cancer patient.